Should a patient with type 2 diabetes receive the scheduled bedtime dose of insulin glargine (Lantus) 15 units when the bedtime glucose is 115 mg/dL, which is within the target range?

Should Bedtime Insulin Glargine Be Administered When Glucose is 115 mg/dL?

Yes, administer the scheduled 15 units of Lantus at bedtime even when the glucose reading is 115 mg/dL, as basal insulin like glargine is designed to provide consistent 24-hour glucose control and should not be withheld based on a single in-range glucose value.

Understanding Basal Insulin Therapy

Basal insulin glargine (Lantus) functions fundamentally differently from correctional or sliding-scale insulin:

• Basal insulin's primary action is to restrain hepatic glucose production and control glucose levels overnight and between meals, not to correct current hyperglycemia 1
• The FDA label specifies that Lantus "should be administered subcutaneously once a day at the same time every day" with dosing individualized based on clinical response, not individual glucose readings 2
• Lantus exhibits a relatively constant glucose-lowering profile over 24 hours, which is why it permits once-daily dosing 2

Why Not to Hold the Dose

Holding basal insulin based on a single bedtime glucose reading creates several problems:

• A glucose of 115 mg/dL (6.4 mmol/L) is within the typical fasting goal range of 90-150 mg/dL recommended for many patients 1
• Withholding the scheduled basal dose will result in inadequate insulin coverage overnight and elevated fasting glucose the following morning 1
• The dose titration of basal insulin should be based on patterns of fasting glucose values over several days, not individual readings 1

Proper Basal Insulin Management

The evidence-based approach to basal insulin dosing involves:

• Titration should occur based on fasting glucose patterns over 3 days to a week, adjusting by 2-4 units once or twice weekly until fasting targets are met 1, 3, 4
• In the landmark Treat-to-Target trial, insulin doses were adjusted based on mean fasting plasma glucose over the previous 3 days, not individual readings 4
• Dose adjustments should only be made under medical supervision with appropriate glucose monitoring 2

When to Consider Dose Reduction

The scheduled dose should only be reduced or held in specific circumstances:

• If there are ≥2 fasting glucose values per week <80 mg/dL (<4.4 mmol/L), then decrease the basal dose by 2 units 1
• If the patient has experienced recent hypoglycemia or has symptoms of hypoglycemia 2
• If the patient is unable to eat or has acute illness that may affect insulin requirements 2

Common Pitfall to Avoid

The most critical error is confusing basal insulin with correctional (sliding-scale) insulin:

• Sliding-scale insulin is used to treat hyperglycemia after it has occurred and should not be the sole insulin regimen for patients with established diabetes 1
• Basal insulin provides foundational glucose control and should be continued as scheduled 1
• The ADA guidelines explicitly state that "do not use rapid- and short-acting insulin at bedtime" for correctional purposes in older adults 1

Practical Algorithm

For a patient on scheduled basal insulin:

1. Administer the scheduled dose at the same time daily unless contraindicated 2
2. Monitor fasting glucose patterns over 3-7 days 3, 4
3. Adjust doses based on patterns, not individual readings 1
4. Only hold or reduce if there is a pattern of hypoglycemia or acute illness 1, 2

The bedtime glucose of 115 mg/dL indicates the current basal insulin regimen is working appropriately and should be continued as prescribed.